[1] 付春燕,黄燚,蒋黎.肿瘤标志物和细胞因子联合检测对早期肺腺癌的诊断价值.实用医院临床杂志,2023,20(4):158-161. [2] 石婕,刘璇,明宗娟,等.细胞因子与肿瘤标志物联合检测对孤立性肺结节良恶性鉴别诊断的价值.中国肺癌杂志,2021,24(6):426-433. [3] 杜毅超,楼美清.肿瘤微环境和肿瘤标志物研究中数字空间多组学技术应用的研究进展.肿瘤学杂志,2023,29(5):430-433. [4] 聂世娟. 贝伐珠单抗辅助治疗非小细胞肺癌伴恶性胸腔积液的临床效果以及炎症因子,肿瘤标志物水平的影响.健康管理,2020,15(7):54-54. [5] 张爱利. 血小板与淋巴细胞比值,乳酸脱氢酶联合肺肿瘤标志物检测应用于肺腺癌诊断价值研究.保健文汇,2021,22(23):76-77. [6] Yanxiao K,Jian W,Shaomu C.Effects of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)targeted combined chemotherapy on immune function,tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma.Pakistan Journal of Medical Sciences,2023,39(3):742-746. [7] 陈阳阳,窦文广,岳军艳,等.多层螺旋CT联合血清相关肿瘤标志物检测在原发性肺癌患者诊断中的应用价值.实用医学影像杂志,2022,23(3):310-313. [8] XiaoDong J,LiRen D,ChuanTao Z,et al. Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. Translational lung cancer research,2021,10(7):3236-3250. [9] 成宇,楼亚玲.肺腺癌骨转移癌痛患者放疗前后细胞因子的分析研究.中国卫生检验杂志,2022,32(14):1730-1734. [10] Bingjie Z,Xianzhao W,Yueyang Q,et al.Differences in serum cytokine levels distinguish between clinically noninvasive lung adenocarcinoma and invasive lung adenocarcinoma:A cross-sectional study.Health science reports,2023,6(9):e1522-e1522. [11] 李辉,汪春新,秦明明,等.肺癌患者血清7项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究.现代检验医学杂志,2021,36(4):5-9,121. [12] Qi T,Qi H,GuanZhou M,et al.Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province,Central China. Journal of clinical laboratory analysis,2020,34(1):e23027-e23027. |